Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Hepatocellular Carcinoma
100%
Diseases
74%
Overall Survival
60%
Malignant Neoplasm
58%
Multiple Myeloma
58%
Neoplasm
53%
Magnetic Resonance Imaging
45%
Chemotherapy
45%
Transitional Cell Carcinoma
35%
Clinical Trial
35%
Tumor
33%
Recurrent Disease
31%
Prostate Cancer
31%
Myelofibrosis
31%
Cancer
27%
Radiation Therapy
27%
Liver Transplantation
27%
Cystectomy
24%
Progression Free Survival
23%
Genetics
22%
Biological Marker
21%
Immunotherapy
20%
Bladder Cancer
20%
Hazard Ratio
20%
Adverse Event
19%
Myeloproliferative Neoplasm
19%
COVID-19
17%
Cisplatin
16%
Arm
15%
Urothelial Cancer
15%
Oncology
15%
Quality of Life
15%
Breast Cancer
15%
Immune Checkpoint Inhibitor
15%
Liver Cirrhosis
14%
Muscle Invasive Bladder Cancer
13%
Cholangiocarcinoma
13%
Ruxolitinib
13%
Systematic Review
13%
Hepatectomy
13%
Polycythemia vera
13%
Chemoradiotherapy
12%
Myeloma
12%
Systemic Therapy
12%
Myelodysplastic Syndrome
12%
Metastatic Carcinoma
12%
Median Follow Up
11%
Biopsy Technique
11%
Prostatectomy
11%
Placebo
11%
Oral
11%
Head and Neck Cancer
11%
Survival Rate
10%
Nivolumab
10%
Platinum
10%
Diffusion MRI
10%
Liver Cancer
10%
Wart Virus
10%
Oropharynx Carcinoma
10%
Fibrosis
10%
Liver Disease
10%
Bladder
10%
Acute Myeloid Leukemia
9%
Infection
9%
Liver Graft
9%
Neoadjuvant Chemotherapy
9%
Lenalidomide
9%
Meta-Analysis
9%
Ovarian Cancer
9%
Neck
9%
Circulating Tumor DNA
9%
Anemia
9%
Pelvis
9%
Squamous Cell Carcinoma
8%
Hematopoietic Cell
8%
Cancer Therapy
8%
Recurrence Free Survival
8%
Lymph Node
8%
Janus Kinase Inhibitor
8%
Health Care Cost
8%
Treatment Option
8%
Morbidity
8%
T Cell
8%
Proportional Hazards Model
8%
Clear Cell Renal Cell Carcinoma
7%
Dexamethasone
7%
Prognostic Factor
7%
Targeted Therapy
7%
Neoadjuvant Therapy
7%
Gemcitabine
7%
Minimal Residual Disease
7%
Sorafenib
7%
Adjuvant Therapy
7%
Magnetic Resonance Elastography
7%
Bortezomib
7%
Area under the Curve
7%
Pathogenesis
7%
Pembrolizumab
7%
Essential Thrombocythaemia
7%
Non Muscle Invasive Bladder Cancer
7%
Keyphrases
Hepatocellular Carcinoma
96%
Overall Survival
53%
Multiple Myeloma
50%
Tumor
45%
Myelofibrosis
39%
Relapsed/refractory multiple Myeloma
31%
Myeloproliferative Neoplasms
28%
95% Confidence Interval
28%
Prostate Cancer
27%
Clinical Trials
24%
Chemotherapy
23%
Hazard Ratio
23%
Progression-free Survival
23%
Phase I Study
22%
Non-muscle Invasive Bladder Cancer (NMIBC)
21%
Polycythemia Vera
20%
Bladder Cancer
20%
Liver Transplantation
20%
High Risk
20%
COVID-19
20%
Phase II Trial
19%
Liver
19%
Immune Checkpoint Inhibitors
18%
In Cancer
18%
Ruxolitinib
17%
Resection
16%
Chronic Graft-versus-host Disease (cGVHD)
15%
Hematopoietic Stem Cells
15%
Meta-analysis
14%
Lenalidomide
14%
United States
14%
Advanced Hepatocellular Carcinoma
14%
Acute Myeloid Leukemia
14%
Clinical Outcomes
13%
Metastatic Urothelial Carcinoma
13%
Adverse Events
13%
Bortezomib
13%
Radical Cystectomy
12%
Mount Sinai
12%
Sorafenib
12%
Circulating Tumor DNA (ctDNA)
12%
Myelodysplastic Syndrome
12%
Chimeric Antigen Receptor T Cells (CAR-T)
12%
Proteolysis Targeting chimera (PROTAC)
12%
T Cells
11%
Radiation Therapy
11%
Myeloma
11%
Cirrhosis
11%
Placebo
11%
Nivolumab
11%
Disease Progression
11%
Human Papillomavirus
11%
Cisplatin
11%
Patient Outcomes
11%
Head-and-neck Cancer
11%
Therapeutic Potential
10%
Graft-versus-host Disease (GvHD)
10%
Systemic Therapy
10%
Cardiac Magnetic Resonance Imaging (cMRI)
10%
Pembrolizumab
10%
Atezolizumab
10%
Transplantation
10%
Metastatic Urothelial Cancer
10%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
10%
Malignancy
9%
Tumor Microenvironment
9%
Bone Marrow
9%
Degrader
9%
Upper Tract Urothelial Carcinoma
9%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
9%
Complete Response
9%
Overall Response Rate
9%
Anemia
9%
Standard of Care
9%
Essential Thrombocythemia
9%
Cancer Patients
9%
Risk Factors
9%
Breast Cancer
9%
Tumor Cells
9%
Thrombocytopenia
9%
Monotherapy
9%
Cancer Immunotherapy
9%
Leukemia
8%
Multiparametric Magnetic Resonance Imaging (mpMRI)
8%
Head-and-neck
8%
Gene Signature
8%
Neoadjuvant Chemotherapy
8%
Proteogenomics
8%
Objective Response Rate
8%
Median Overall Survival
8%
Risk Stratification
8%
Cancer Cells
8%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
8%
Treatment Options
8%
Radiotherapy
8%
Enhancer of Zeste Homolog 2 (EZH2)
8%
Newly Diagnosed multiple Myeloma
8%
Recurrence-free Survival
8%
Improved Outcomes
8%
Quality of Life
8%